The ADVanced Organ Support (ADVOS) Hemodialysis System in Postoperative Cardiogenic Shock and Multiple Organ Failure:...

The management of multiple organ failure in the vulnerable cohort of cardiac surgery patients with cardiogenic shock remains a significant challenge, often impairing patient survival. A multimodal approach at targeting organ dysfunction seems to be a promising strategy, encompassing both hemodynamic support as well as differentiated organ replacement therapy.

In our retrospective study we examined the impact of the ADVOS (advanced organ support) system on overall outcomes and survival in an all-comers group of 22 cardiac surgery patients with postoperative cardiogenic shock and multiple organ failure.

The objective of the study was to assess the feasibility and potential benefits of ADVOS treatment in this patient population.

The standard care management in combination with ADVOS therapy corrected acid-base balance (pH 7.33 vs. 7.44, p = 0.001; base excess -3.2 vs. 2.4 mmol/L, p < 0.001). This contributed to restoring hemodynamic balance after two consecutive ADVOS treatments (vasoactive inotropic score (VIS) 59 vs. 21, p = 0.007, noradrenaline 0.470 vs. 0.180 µg/kg/min, p = 0.009).

Our findings indicate that ADVOS treatment is both feasible and safe, with a substantial proportion of patients demonstrating improvements in organ function and overall outcomes.